Wize Pharma, Inc.·4

Dec 17, 4:58 PM ET

Danenberg Noam 4

4 · Wize Pharma, Inc. · Filed Dec 17, 2019

Insider Transaction Report

Form 4
Period: 2019-12-13
Danenberg Noam
Chief Operating Officer
Transactions
  • Other

    Future Investment Rights

    2019-12-1331,14694,382 total(indirect: See Footnote)
    Exercise: $0.27From: 2019-12-13Exp: 2024-12-12Common Stock (31,146 underlying)
  • Conversion

    Common Stock

    2019-12-13+752,581952,681 total(indirect: See Footnote)
  • Other

    Warrants

    2019-12-13+1,505,1621,505,162 total(indirect: See Footnote)
    Exercise: $0.27Exp: 2024-12-12Common Stock (1,505,162 underlying)
Footnotes (4)
  • [F1]Outstanding debt converted at $0.27 per share.
  • [F2]752,581 shares held by Mobigo Inc. and 200,100 previously held shares directly.
  • [F3]Exercisable five days following the public announcement of positive clinical data results for LO2A
  • [F4]Securities held by Mobigo Inc.

Documents

1 file
  • 4
    ownership.xmlPrimary